You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

germinal center B-cell

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Recurrent DLBCL Germinal Center B-Cell Type, Recurrent Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma Trial (Belinostat,

Not yet recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
  • +5 more
  • (no location specified)
Dec 2, 2022

Recurrent DLBCL Activated B-Cell Type, Recurrent DLBCL Germinal Center B-Cell Type, Recurrent High Grade B-Cell Lymphoma With

Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type
  • +8 more
  • Biospecimen Collection
  • +3 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Mar 8, 2023

Burkitt Lymphoma, High-grade B-cell Lymphoma, T-cell/Histocyte-rich Large B-cell Lymphoma Trial run by the NCI (Rituximab,

Suspended
  • Burkitt Lymphoma
  • +4 more
  • Rituximab
  • +6 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

DLBCL, DLBCL Germinal Center B-Cell Type, DLBCL, Not Otherwise Specified Trial in Columbus (Molecular Nanotechnology)

Recruiting
  • Diffuse Large B-Cell Lymphoma
  • +3 more
  • Molecular Nanotechnology
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Jun 2, 2022

DLBCL Germinal Center B-Cell Type Trial in China (Selinexor, Rituximab, Cyclophosphamide)

Recruiting
  • DLBCL Germinal Center B-Cell Type
  • Guangzhou, Guangdong, China
  • +5 more
Aug 16, 2022

Mature B-Cell Tumor, Non Hodgkin Lymphoma, DLBCL Trial (SGR-1505)

Not yet recruiting
  • Mature B-Cell Neoplasm
  • +25 more
  • (no location specified)
Sep 14, 2022

B-ALL, DLBCL, B ALL Trial in New York (131-I Apamistamab, CAR T-cell)

Recruiting
  • B-ALL
  • +10 more
  • 131-I Apamistamab
  • CAR T-cell
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Mar 7, 2022

Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia Trial in Miami (Acalabrutinib,

Terminated
Has Results
  • Diffuse Large B Cell Lymphoma
  • +3 more
  • Miami, Florida
    University of Miami
Aug 23, 2022

ALK-Positive Large B-Cell Lymphoma, Burkitt-Like Lymphoma With 11q Aberration, DLBCL Activated B-Cell Type Trial in United

Active, not recruiting
  • ALK-Positive Large B-Cell Lymphoma
  • +34 more
  • Phoenix, Arizona
  • +32 more
Jan 3, 2023

DLBCL Trial in Houston (Acalabrutinib, Cyclophosphamide, Doxorubicin Hydrochloride)

Recruiting
  • Diffuse Large B-Cell Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Jul 10, 2022

Ann Arbor Stage III DLBCL, Ann Arbor Stage IIX (Bulky) DLBCL, Ann Arbor Stage IV DLBCL Trial in United States (drug, other,

Suspended
  • Ann Arbor Stage III Diffuse Large B-Cell Lymphoma
  • +20 more
  • Tucson, Arizona
  • +110 more
Jan 31, 2023

COVID-19 Trial in Paris (Lymph node aspiration / Blood sampling)

Recruiting
  • COVID-19
  • Lymph node aspiration / Blood sampling
  • Paris, France
    GH Broca-Cochin-Hôtel-Dieu CIC 1417 Cochin-Pasteur
Jul 19, 2023

DLBCL, DLBCL Activated B-Cell Type, DLBCL Germinal Center B-Cell Type Trial in Chicago (Cyclophosphamide, Doxorubicin

Active, not recruiting
  • Diffuse Large B-Cell Lymphoma
  • +6 more
  • Chicago, Illinois
    Northwestern University
Apr 30, 2021

Hematologic Cancer Trial in Israel, United States (ABBV-101)

Not yet recruiting
  • Hematologic Cancer
  • Lone Tree, Colorado
  • +7 more
Feb 22, 2023

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent DLBCL, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma Trial

Active, not recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Jacksonville, Florida
  • +11 more
Jan 12, 2023

Lymphoma Trial in United States (itacitinib, ibrutinib)

Completed
  • Lymphoma
  • Scottsdale, Arizona
  • +20 more
Nov 14, 2022

Non-hodgkin Lymphoma Trial (HY004)

Not yet recruiting
  • Non-hodgkin Lymphoma
  • HY004
  • (no location specified)
Aug 21, 2023

B-cell Acute Lymphoblastic Leukemia Trial (HY004, Cyclophosphamide, Fludarabine Phosphate)

Not yet recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • HY004
  • +2 more
  • (no location specified)
Aug 18, 2023

B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma Trial in Beijing (CD19/CD22-bispecific CAR-T

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • +2 more
  • CD19/CD22-bispecific CAR-T cells
  • Beijing, Beijing, China
    Liang Wang
Oct 7, 2023

Diffuse Large B Cell Lymphoma Trial in Shanghai (Zanubrutinib, Polatuzumab vedotin and Rituximab)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • Zanubrutinib, Polatuzumab vedotin and Rituximab
  • Shanghai, Shanghai, China
    Zhongshan Hospital，Fudan University
Jul 10, 2023

Diffuse Large B Cell Lymphoma Trial in Shanghai (Zanubrutinib, Polatuzumab Vedotin, Rituximab)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • Zanubrutinib, Polatuzumab Vedotin, Rituximab
  • Shanghai, Shanghai, China
    Zhongshan Hospital，Fudan University
Jul 10, 2023

Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic Hodgkin Lymphoma, Recurrent

Not yet recruiting
  • Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
  • +21 more
  • Biopsy
  • +8 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Apr 7, 2023

Treatment of Diffuse Large B Cell Lymphoma - BRA-DLBCL

Recruiting
  • Diffuse Large B Cell Lymphoma
    • Salvador, Bahia, Brazil
    • +9 more
    Jul 24, 2023

    B-Cell Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia Trial in Tampa (Tecartus)

    Recruiting
    • B-Cell Lymphoblastic Leukemia
    • Acute Lymphoblastic Leukemia
    • Tampa, Florida
      Moffitt Cancer Center
    Nov 28, 2023

    High-Dose Methotrexate Clearance in Diffuse Large B-Cell

    Recruiting
    • Central Nervous System Lymphoma
    • Diffuse Large B-Cell Lymphoma
    • Non-Interventional Study
    • Columbus, Ohio
      Ohio State University Comprehensive Cancer Center
    Sep 8, 2023